Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted. 
No comment yet.
Sign up to comment
|
Scoop.it!
On June 21, Todd Hagopian recommended Insys Therapeutics (INSY). Since then, the stock has gained nearly 20%. After a stock runs like this, many investors are tempted to sell. However, in situations like this, I’ve found it valuable to know which side of the trade the people with superior track records are on before making any trading decisions.
Shinji's insight:
Todd Hagopian: This week, the FDA approved Syndros, which will be INSY’s 2nd FDA-approved Cannabis-based drug. Syndros is an appetite-boosting drug, which will help people dealing with Cancer, or AIDS-related weight loss. The sales forecast for this drug are in the hundreds of millions, and should effectively double the revenue of the company over the next few years. Kam: Are you buying or selling Insys on this news? Hagopian: My $32 price target was based off of $500M in annual sales, a number which should be relatively reasonable given this second approved drug. My $32 price target is about a 100% increase to today’s selling price, making this stock still a bargain. Kam: You talked about, Insys, GW Pharmaceuticals and Cara Therapeutics as forming a new sector of biotech. It seems like there has been a lot of news about all three lately. Insys Therapeutics INSY - Nasdaq
|
